(416c) Lipid-Polymeric Hybrid Nanoparticle Based Nicotine Vaccine: Size Matters

Authors: 
Zhao, Z., Virginia Tech
Hu, Y., Virginia Tech
Zhang, C., Virginia Tech

Lipid-polymeric
hybrid nanoparticle based nicotine vaccine: size matters

Zongmin Zhaoǂ, Yun
Hu, Reece Hoerle, Meaghan Devine, Chenming Zhang

Department of Biological Systems
Engineering, Virginia Tech, Blacksburg, VA 24061

ǂPresenting author

Email addresses:

Zongmin Zhao: zmzhao@vt.edu

Yun Hu: hyun86@vt.edu

Reece Hoerle: rhoerle@vt.edu

Meaghan Devine: meaghd1@vt.edu

Chenming Zhang: chzhang2@vt.edu

Abstract

Tobacco use is prevalent worldwide and has
consistently been the top preventable cause of many serious diseases, resulting
in huge mortality, morbidity, and economic loss in recent decades. Due to the
limited success of FDA approved pharmacological therapies, it is necessary to
develop more effective treatment for smoking cessation. Currently, nicotine
vaccine that can induce nicotine specific antibodies is considered as a
promising approach against tobacco addiction. However, traditional protein-hapten
conjugate nicotine vaccines have shown less than desired immunological efficacy
due to their poor recognition and internalization by immune cells. Previous
study in our group showed that negatively charged nanohorn supported liposome
could effectively enhance the immunogenicity of nicotine protein conjugate
based vaccine. In this study, nanohorn was substituted with Poly
(lactic-co-glycolic acid) (PLGA) nanoparticle (NP) and a novel lipid-polymeric hybrid
NP based nicotine vaccine was developed. In particular, the effects of particle
size on the immunogenicity of hybrid NP based vaccine was investigated. 100 nm
hybrid NPs were found to be taken up by dendritic cells more efficiently than
500 nm hybrid NPs. Mice immunization results demonstrated that both 100 nm and
500 nm nanovaccines could induce strong immune response against nicotine.
However, a significantly higher titer of antibody against nicotine was achieved
by 100 nm nanovaccine than 500 nm nanovaccine. Moreover, no evidence of
systemic toxicity was observed on mice immunized with all the hybrid NP based
nicotine vaccines. These results from this study suggest that lipid-polymeric
NP based nicotine vaccine is a promising candidate for treating nicotine
dependence.